Recent quotes:

Efficacy, Safety, and Tolerability of Three Doses of Sulthiame in Patients With Obstructive Sleep Apnea. A Randomized, Double-blind, Placebo Controlled, Dose-ranging Study (STM-042/K) | B14. LATE BREAKING ABSTRACTS: SCIENCE THAT WILL IMPACT CLINICAL CARE

Empty heading Efficacy, Safety, and Tolerability of Three Doses of Sulthiame in Patients With Obstructive Sleep Apnea. A Randomized, Double-blind, Placebo Controlled, Dose-ranging Study (STM-042/K)
#apnea #diamox #sulthiame - atsjournals.org

Epilepsy Drug Shows Promise in Reducing Obstructive Sleep Apnea Symptoms

Patients who took the carbonic anhydrase inhibitor experienced fewer breathing interruptions during sleep and improved oxygen levels. The apnea-hypopnea index (AHI3a), which tracks the frequency of respiratory pauses, decreased by 17.8% in those on the lowest dose (100 mg), 34.8% on the medium dose (200 mg), and 39.9% on the highest dose (300 mg). When using the AHI4 measure for when oxygen levels were more severely affected, the reduction in respiratory pauses was nearly 50%. Patients also reported feeling less daytime sleepiness while on the medication. These findings are based on a double-blind, randomized, placebo-controlled trial presented at the ERS Congress by Jan Hedner, MD, PhD, professor of respiratory medicine at Sahlgrenska University Hospital and the University of Gothenburg in Sweden and lead author of the study.2
#apnea #diamox #sulthiame - ajmc.com

Acetazolamide: Old drug, new evidence? - PMC

Epilepsy is associated with increased brain inflammatory cytokines, and seizures induce these increases. These, in turn, activate nuclear transcription of NF‐kB, complement and chemokines, which result in inflammation in the brain. Brain inflammation is proconvulsive, and some purport that antiepileptic drugs may have a role as an anti‐inflammatory effect. During neuronal injury, ASICs are activated, and these activate inflammasomes leading to neuronal injury and blockage of ASICs will reduce this injury. 41 Acetazolamide decreases the levels of inflammatory cytokines IL‐6, TNF alpha and IL‐1beta in rat models of epilepsy. Acetazolamide also reduces inflammation by reducing cytokine expression, further contributing to its antiepileptic effect. 41 , 42
#cytokines #apnea #diamox #epilepsy - ncbi.nlm.nih.gov

Acetazolamide for OSA and Central Sleep Apnea: A Comprehensive Systematic Review and Meta-Analysis - PubMed

Overall, acetazolamide vs control lowered the AHI by -0.7 effect sizes (95% CI, -0.83 to -0.58; I2 = 0%; moderate QoE) that corresponded to a reduction of 37.7% (95% CI, -44.7 to -31.3) or 13.8/h (95% CI, -16.3 to -11.4; AHIControl = 36.5/h). The AHI reduction was similar in OSA vs CSA, but significantly greater with higher doses (at least up to 500 mg/d). Furthermore, acetazolamide improved oxygen saturation nadir by +4.4% (95% CI, 2.3 to 6.5; I2 = 63%; no evidence of effect modification; very low QoE) and several secondary outcomes that included sleep quality measures and BP (mostly low QoE).
#medicalindustrialcomplex #sleep-apnea #diamox - pubmed.ncbi.nlm.nih.gov

Acute and long-term effects of acetazolamide in presumed high loop gain sleep apnea - ScienceDirect

Acetazolamide (AZT) is a carbonic anhydrase inhibitor [25]. For OSA patients traveling to high-altitude, AZT improves oxygenation and periodic breathing [26,27]. In OSA patients at sea level, AZT reduces loop gain especially in patients with heart failure and chronic opioids use [[28], [29], [30], [31], [32], [33], [34]]. A meta-analysis showed that AZT improves central but not obstructive sleep apnea at sea-level [35].
#sleep-apnea #diamox - sciencedirect.com